Lipophen MC 20% Injection

Adult dosage

Administer 1-2g of fat per day per kilogram of body weight (equivalent to approximately 5-10 milliliters of this drug) by slow intravenous infusion. The infusion rate should not exceed 0.05-0.1g (equivalent to 0.25-0.5 milliliters) of fat per kilogram of body weight in the first 15 minutes; if no adverse effects occur, it can be increased to 0.15-0.2g (0.75-1.0 milliliters) per kilogram of body weight per hour. Minimum of 16 hours per day

Children's dosage

Neonates: Administer 2-3g of fat per day per kilogram of body weight (equivalent to approximately 10-15 milliliters of this drug) by slow intravenous infusion, with a maximum of 4g (equivalent to 20 milliliters) allowed. Infants: Per kilogram of body weight

This medication should be used with great caution when administered to premature infants and low-birth-weight infants, as it may increase plasma free fatty acid levels. It should not be administered to premature infants with severe respiratory diseases, as this may lead to serious complications due to fat accumulation in the pulmonary vasculature. It should not be used in patients with pathological hyperlipidemia, lipid metabolism disorders, ketoacidosis, hypoxia, thrombosis, acute myocardial infarction, or liver disease. It is also contraindicated in pregnant women, and patients with a history of allergic reactions should be observed closely. Caution should be exercised in patients suspected of metabolic acidosis, pulmonary disease, anemia, or fat embolism. During administration, blood tests, liver function tests, and platelet counts should be closely monitored, and administration should be stopped immediately if adverse reactions occur. This medication should be given slowly while carefully monitoring blood lipid levels, as rapid administration can cause fluid imbalance or lung damage. Diabetic patients should be especially cautious, as ketoacidosis may worsen. The safety of this drug in pregnant or nursing women has not been established; it should only be used when absolutely necessary, with thorough monitoring through various tests. In children, especially premature and low-birth-weight infants, due to immature fat excretion capacity, the dosage should be limited, and blood lipid levels should be carefully monitored. In the case of overdose, symptoms such as liver enlargement, anemia, and coagulopathy may appear, and administration should be stopped immediately, followed by appropriate treatment. This medication must be administered exclusively through a peripheral venous infusion, should not be mixed with other medications, and any remaining medication should be discarded. Additionally, it is recommended to administer more than 40% of the total calories along with carbohydrates.

Serious side effects

Dyspnea, cyanosis, cholestasis jaundice in the centrilobular region, jaundice

Mild side effects

Thrombocytopenia, leukopenia, brown pigmentation in the reticuloendothelial system, liver enlargement, transient increase in liver function test values, hyperlipidemia, increased coagulability, nausea, vomiting, allergic reactions, headache, flushing, fever, sweating, chills, drowsiness, chest pain, back pain, dizziness, edema, overload syndrome

This medication should be stored in a cool place below 25 degrees Celsius, in a sealed container to avoid contact with air. This will help maintain the effectiveness of the drug.

Appearance

A milky white suspension in a glass container for injection

Package unit

100, 250, 500 milliliters x manufacturer's packaging unit